SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Kintara Therapeutics, Inc. – ‘S-1/A’ on 7/11/19 – ‘R12’

On:  Thursday, 7/11/19, at 4:17pm ET   ·   Accession #:  1213900-19-12524   ·   File #:  333-232332

Previous ‘S-1’:  ‘S-1’ on 6/25/19   ·   Next:  ‘S-1’ on 8/1/19   ·   Latest:  ‘S-1/A’ on 10/27/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/11/19  DelMar Pharmaceuticals, Inc.      S-1/A                 71:7.9M                                   Edgar Agents LLC/FA

Pre-Effective Amendment to Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Amendment No. 1 to Form S-1                         HTML   1.11M 
 2: EX-23.1     Consent of Ernst & Young, LLP                       HTML     19K 
 9: R1          Document and Entity Information                     HTML     34K 
10: R2          Consolidated Condensed Interim Balance Sheets       HTML     90K 
11: R3          Consolidated Condensed Interim Balance Sheets       HTML     41K 
                (Parenthetical)                                                  
12: R4          Consolidated Condensed Interim Statements of Loss   HTML     63K 
                and Comprehensive Loss                                           
13: R5          Consolidated Statements of Changes in               HTML    112K 
                Stockholders' Equity                                             
14: R6          Consolidated Condensed Interim Statements of Cash   HTML     84K 
                Flows                                                            
15: R7          Going Concern, Nature of Operations, and Corporate  HTML     40K 
                History                                                          
16: R8          Significant Accounting Policies                     HTML     81K 
17: R9          Valent Technologies, LLC                            HTML     28K 
18: R10         Derivative Liability                                HTML     61K 
19: R11         Stockholders' Equity                                HTML    227K 
20: R12         Financial Instruments                               HTML     36K 
21: R13         Related Party Transactions                          HTML     22K 
22: R14         Current and Deferred Income Taxes                   HTML     37K 
23: R15         Commitments and Contingencies                       HTML     25K 
24: R16         Supplementary Statement of Cash Flows Information   HTML     31K 
25: R17         Financial Risk Management                           HTML     34K 
26: R18         Subsequent Events                                   HTML     32K 
27: R19         Significant Accounting Policies (Policies)          HTML    129K 
28: R20         Significant Accounting Policies (Tables)            HTML     25K 
29: R21         Derivative Liability (Tables)                       HTML     57K 
30: R22         Stockholders' Equity (Tables)                       HTML    202K 
31: R23         Financial Instruments (Tables)                      HTML     28K 
32: R24         Current and Deferred Income Taxes (Tables)          HTML     47K 
33: R25         Supplementary Statement of Cash Flows Information   HTML     30K 
                (Tables)                                                         
34: R26         Financial Risk Management (Tables)                  HTML     33K 
35: R27         Going Concern, Nature of Operations, and Corporate  HTML     37K 
                History (Details)                                                
36: R28         Significant Accounting Policies (Details)           HTML     30K 
37: R29         Significant Accounting Policies (Details Textual)   HTML     45K 
38: R30         Valent Technologies, LLC (Details)                  HTML     49K 
39: R31         Derivative Liability (Details)                      HTML     37K 
40: R32         Derivative Liability (Details 1)                    HTML     41K 
41: R33         Derivative Liability (Details Textual)              HTML     71K 
42: R34         Stockholders' Equity (Details)                      HTML    100K 
43: R35         Stockholders' Equity (Details 1)                    HTML     30K 
44: R36         Stockholders' Equity (Details 2)                    HTML     37K 
45: R37         Stockholders' Equity (Details 3)                    HTML     40K 
46: R38         Stockholders' Equity (Details 4)                    HTML    118K 
47: R39         Stockholders' Equity (Details 5)                    HTML     38K 
48: R40         Stockholders' Equity (Details 6)                    HTML     30K 
49: R41         Stockholders' Equity (Details 7)                    HTML     51K 
50: R42         Stockholders' Equity (Details 8)                    HTML     35K 
51: R43         Stockholders' Equity (Details 9)                    HTML     58K 
52: R44         Stockholders' Equity (Details 10)                   HTML     90K 
53: R45         Stockholders' Equity (Details 11)                   HTML     33K 
54: R46         Financial Instruments (Details)                     HTML     28K 
55: R47         Related Party Transactions (Details)                HTML     23K 
56: R48         Current and Deferred Income Taxes (Details)         HTML     47K 
57: R49         Current and Deferred Income Taxes (Details 1)       HTML     44K 
58: R50         Current and Deferred Income Taxes (Details          HTML     46K 
                Textual)                                                         
59: R51         Commitments and Contingencies (Details)             HTML     27K 
60: R52         Stockholders' Equity (Details Textual)              HTML     91K 
61: R53         Stockholders' Equity (Details Textual 1)            HTML     66K 
62: R54         Stockholders' Equity (Details Textual 2)            HTML     52K 
63: R55         Stockholders' Equity (Details Textual 3)            HTML     46K 
64: R56         Supplementary Statement of Cash Flows Information   HTML     43K 
                (Details)                                                        
65: R57         Financial Risk Management (Details)                 HTML     27K 
66: R58         Financial Risk Management (Details 1)               HTML     28K 
67: R59         Financial Risk Management (Details Textual)         HTML     48K 
68: R60         Subsequent Events (Details)                         HTML     51K 
70: XML         IDEA XML File -- Filing Summary                      XML    133K 
69: EXCEL       IDEA Workbook of Financial Reports                  XLSX    101K 
 3: EX-101.INS  XBRL Instance -- dmpi-20190331                       XML   2.20M 
 5: EX-101.CAL  XBRL Calculations -- dmpi-20190331_cal               XML    142K 
 6: EX-101.DEF  XBRL Definitions -- dmpi-20190331_def                XML    703K 
 7: EX-101.LAB  XBRL Labels -- dmpi-20190331_lab                     XML   1.14M 
 8: EX-101.PRE  XBRL Presentations -- dmpi-20190331_pre              XML    897K 
 4: EX-101.SCH  XBRL Schema -- dmpi-20190331                         XSD    211K 
71: ZIP         XBRL Zipped Folder -- 0001213900-19-012524-xbrl      Zip    171K 


‘R12’   —   Financial Instruments


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.19.2
Financial Instruments
9 Months Ended
Fair Value Disclosures [Abstract]  
Financial instruments
6Financial instruments

 

The Company has financial instruments that are measured at fair value. To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:

 

Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and

 

Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

 

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.

 

The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, related party payables and derivative liability. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.

 

Derivative liability

 

The Company accounts for certain warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock, on the understanding that in compliance with applicable securities laws, the warrants require the issuance of securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. The Company has used a Black-Scholes Option Pricing Model (based on a closed-form model that uses a fixed equation) to estimate the fair value of the share warrants. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change in the estimates (specifically probabilities and volatility) used may cause the value to be higher or lower than that reported. The estimated volatility of the Company’s common stock at the date of issuance, and at each subsequent reporting period, is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent to their remaining contractual term.

 

a)Fair value of derivative liability

 

The derivative is not traded in an active market and the fair value is determined using valuation techniques. The Company uses judgment to select a variety of methods to make assumptions that are based on specific management plans and market conditions at the end of each reporting period. The Company uses a fair value estimate to determine the fair value of the derivative liability. The carrying value of the derivative liability would be higher, or lower, as management estimates around specific probabilities change. The estimates may be significantly different from those amounts ultimately recorded in the consolidated financial statements because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market. All changes in the fair value are recorded in the consolidated statement of operations and comprehensive loss each reporting period. This is considered to be a Level 3 financial instrument as volatility is considered a Level 3 input.

 

The Company has the following liabilities under the fair value hierarchy:

 

   March 31, 2019 
Liability  Level 1   Level 2   Level 3 
                
Derivative liability  $-   $-   $265 

 

   June 30, 2018 
Liability  Level 1   Level 2   Level 3 
                
Derivative liability  $-   $-   $1,117

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-1/A’ Filing    Date    Other Filings
Filed on:7/11/19CORRESP
3/31/1910-Q
6/30/1810-K
 List all Filings 
Top
Filing Submission 0001213900-19-012524   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 1:04:54.1pm ET